Prophylactic cranial irradiation in ES-SCLC: The ongoing debate from the past to the immunotherapy Era".

Clin Transl Radiat Oncol · 2026 · PMC13049582 · PMID 41938987

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, a phase III trial exploring newer immunotherapies as the combination of Tislelizumab plus chemotherapy, PCI showed a trend toward improved mPFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.